Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3648 USD | -1.91% | -1.00% | -81.29% |
May. 15 | Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 15 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M | MT |
Financials (USD)
Sales 2022 | 10.88 | Sales 2023 | 19.59 | Capitalization | 4.9M |
---|---|---|---|---|---|
Net income 2022 | -25M | Net income 2023 | -14M | EV / Sales 2022 | 568,219 x |
Net cash position 2022 | 3.04M | Net cash position 2023 | 385K | EV / Sales 2023 | 230,324 x |
P/E ratio 2022 |
-0.19
x | P/E ratio 2023 |
-0.29
x | Employees | 19 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.75% |
Latest transcript on Agile Therapeutics, Inc.
1 week | +0.92% | ||
Current month | +3.02% | ||
1 month | -0.96% | ||
3 months | -48.20% | ||
6 months | -83.02% | ||
Current year | -80.93% |
Managers | Title | Age | Since |
---|---|---|---|
Al Altomari
CEO | Chief Executive Officer | 65 | 04-01-31 |
Scott Coiante
DFI | Director of Finance/CFO | 57 | 10-11-30 |
Paul Korner
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-08-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Al Altomari
CEO | Chief Executive Officer | 65 | 04-01-31 |
Seth Fischer
BRD | Director/Board Member | 68 | 16-07-27 |
John Hubbard
BRD | Director/Board Member | 67 | 14-11-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 0.3648 | -1.91% | 11 996 |
24-06-07 | 0.3719 | +2.65% | 2,315 |
24-06-06 | 0.3623 | -0.06% | 36,635 |
24-06-05 | 0.3625 | +0.14% | 76,635 |
24-06-04 | 0.362 | -1.76% | 6,606 |
Delayed Quote OTC Markets, June 10, 2024 at 10:48 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-80.93% | 2.55M | |
+18.06% | 125B | |
+13.24% | 108B | |
-7.44% | 24.21B | |
+1.98% | 22.78B | |
-10.63% | 17.96B | |
-41.74% | 16.43B | |
-12.66% | 16.37B | |
+0.94% | 13.58B | |
+26.44% | 11.66B |
- Stock Market
- Equities
- AGRX Stock